Anti-SMMHC/MYH11 Monoclonal Antibody for WB, ELISA - P35749

Core Product Specifications and Parameters

Biological Background: Myosin-11 (SMMHC/MYH11) Function and Localization

• Myosin-11, also known as smooth muscle myosin heavy chain (SMMHC), is a motor protein that powers muscle contraction via actin binding and ATP hydrolysis.
• Encoded by the MYH11 gene, alternative splicing generates isoforms, including isoform 1 prevalent in slowly contracting tonic smooth muscles.
• It localizes to the thick filament of smooth muscle myofibrils and has been detected in melanosomes, suggesting extra-contractile roles.
• Predominantly expressed in smooth muscle tissues such as the umbilical artery, bladder, esophagus, and trachea.
• Post-translational modifications, including phosphorylation and methylation, regulate myosin-11 assembly, activity, and disease associations.
• Mutations and chromosomal rearrangements involving MYH11 are linked to aortic aneurysm and vascular pathologies, and it is recognized as a proto-oncogene in certain contexts.

Experimental Guidance and Technical Tips

• The immunogen corresponds to amino acids 1160–1313; consider this region when designing peptide competition assays or epitope mapping.
• For Western blot, validate the antibody with lysates from smooth muscle cell lines or tissues (human, mouse, rat). Note the high molecular weight (~227 kDa); use low-percentage SDS-PAGE gels and extended transfer times.
• In ELISA, optimize coating antigen concentration and antibody dilution using recombinant protein or peptide. Cross-reactivity with other myosin heavy chains should be assessed empirically.
• This antibody has not been tested in IHC or IF; if required, perform pilot experiments with appropriate fixation and permeabilization protocols.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio serves as a comprehensive IVD raw-material sourcing partner, supplying validated antibodies, optimized antibody pairs, and bulk ancillary reagents for diagnostic development. For researchers and manufacturers focusing on smooth muscle biology or myosin-related diseases, we facilitate access to this monoclonal antibody and other rare-target raw materials, bridging the gap from concept to clinic.